Toggle light / dark theme

Braintree founder Bryan Johnson, MBA’07, invests in bold ventures on the next frontier.

Bryan Johnson is determined to explore the depths of your mind and help save humanity from its direst threats.

“The biggest revolutions that have happened over the past couple of decades have largely been done on silicon—the transistors we build, the computers we have, the internet, our smartphones,” said Johnson, MBA’07. “The next great revolutions will be evolving our cognition and predictably engineering atoms, molecules, organisms and complex systems.”

https://www.youtube.com/watch?v=Ily4m823GDM&t=1s

https://www.youtube.com/watch?v=PsK-pPjW020&t=1s

Circa 2016 could cure viruses in no time.


When you get right down to it, developing vaccines is about data and luck. Scientists start with a set of variables—what drugs a virus responds to, how effectively, and for whom—and then it’s a whole lot of trial and error until they stumble upon a cure.

One of the most exciting possibilities in medical research right now is how technology like machine learning could help researchers rapidly process those enormous sets of data, more quickly leading to cures. This is already starting to happen: In a study published Wednesday in the journal Macromolecules, researchers from IBM and Singapore’s Institute of Bioengineering and Nanotechnology reveal a breakthrough that could help prevent deadly virus infections. With the help of IBM super computer Watson, they hope their finding will soon make its way into vaccines.

New transhumanism and biohacking story out by one of Asia’s most influential newspapers: South China Morning Post:


From brain supplements to chip implants to nootropics, humans are using technology, medicine and extreme diets to improve their brainpower, health and longevity.

This year marks the Eighth Review Conference (RevCon) of the Biological Toxins and Weapons Convention (BWC). At the same time, ongoing international efforts to further and more deeply investigate the brain’s complex neuronal circuitry are creating unprecedented capabilities to both understand and control neurological processes of thought, emotion, and behavior. These advances have tremendous promise for human health, but the potential for their misuse has also been noted, with most discussions centering on research and development of agents that are addressed by existing BWC and Chemical Weapons Convention (CWC) proscriptions. In this article, we discuss the dual-use possibilities fostered by employing emergent biotechnologic techniques and tools—specifically, novel gene editors like clustered regular interspaced short palindromic repeats (CRISPR)—to produce neuroweapons. Based on our analyses, we posit the strong likelihood that development of genetically modified or created neurotropic substances will advance apace with other gene-based therapeutics, and we assert that this represents a novel—and realizable—path to creating potential neuroweapons. In light of this, we propose that it will be important to re-address current categorizations of weaponizable tools and substances, so as to better inform and generate tractable policy to enable improved surveillance and governance of novel neuroweapons.

Keywords: : CRISPR, Gene editing, Neuroweapon, Neurotherapeutic pathways, Dual-use neuroscience, Biosecurity policy.

T his year marks the Eighth Review Conference (RevCon) of the Biological Toxins and Weapons Convention (BWC), the purpose of which is to ensure that the convened parties’ directives continue to be relevant to and viable for prohibiting the development, production, and stockpiling of biological weapons in the face of newly emerging scientific advancements and biotechnologies. Apropos of issues raised at previous RevCons and elsewhere, there are growing concerns about current and future weaponization of neurobiological agents and tools (ie, “neuroweapons”1–6).

A, C57BL/6J mice were genetically engineered using CRISPR–Cas9 genomic editing to encode 288L and 330R in mDPP4 on one chromosome (heterozygous, 288/330+/−) or on both chromosomes (homozygous, 288/330+/+). b, Northern blot of mDPP4 mRNA expression. c, Immunohistochemistry (IHC) of mDPP4 protein in the lungs, brain and kidneys of individual C57BL/6J wild-type (WT), 288/330+/− and 288/330+/+ mice. d, Viral titres for MERS-CoV at 3 days post-infection from C57BL/6J WT, 288/330+/− and 288/330+/+ (all n = 4) mice infected with 5 × 105 plaque-forming units (p.f.u.) of the indicated viruses. Bar graphs show means + s.d.